Mizuho Securities analyst Difei Yang maintained a Hold rating on Alder Biopharmaceuticals (ALDR) today and set a price target of $18.00. The company’s shares closed last Monday at $18.88, close to its 52-week high of $19.12.
According to TipRanks.com, Yang is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -3.3% and a 33.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals Inc, Audentes Therapeutics, and Revance Therapeutics.
Currently, the analyst consensus on Alder Biopharmaceuticals is a Hold with an average price target of $19.80.
See today’s analyst top recommended stocks >>
Based on Alder Biopharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $58.41 million. In comparison, last year the company had a GAAP net loss of $60.92 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which discovers, develops and commercializes various therapeutic antibodies. Its product portfolio includes ALD1910, a preclinical product candidate also in development as a migraine prevention therapy.
